ESR1 and breast cancer: As a proportion of metastatic cancer cells of ERα‐positive breast cancer are likely to have evolved to proliferate and survive under endocrine therapy, it may not seem surprising that these resistance mechanisms can strongly differ from those responsible for intrinsic treatment resistance (Dalmau et al., 2014).